利培酮联合文拉法辛治疗精神分裂症伴焦虑症状对照研究

目的 探讨利培酮联合文拉法辛治疗精神分裂症伴焦虑症状的临床疗效和安全性.方法 将68例精神分裂症伴焦虑症状患者随机分为两组,每组34例,两组均口服利培酮治疗,研究组联合文拉法辛治疗,观察8周.于治疗前后采用阳性与阴性症状量表、汉密顿焦虑量表、副反应量表评定临床疗效和不良反应.结果 治疗后研究组阳性与阴性症状量表、汉密顿焦虑量表评分均较治疗前显著下降(P＜0.01),对照组仅阳性与阴性症状量表评分有显著下降(P＜0.01);研究组阳性与阴性症状量表总分、阴性症状因子分及汉密顿焦虑量表评分均显著低于对照组(P＜0.01);治疗8周末,研究组有效率为88.24%,对照组为64.71%,研究组显著高于对照组(χ2=5.231,P＜0.05).两组不良反应均轻微,发生率差异无显著性(P＞0.05).结论利培酮联合文拉法辛治疗能有效改善精神分裂症患者的阴性症状及其焦虑症状,显著提高临床疗效,且安全性高,依从性好.

A control study of risperidone plus venlafaxine in the treatment of schizophrenia with anxiety symptoms

Objective To explore the cclinical efficacy and safety of risperidone plus venlafaxine in the treatment of schizophrenia with anxiety symptoms （SAS）. Methods Sixty-eight SAS patients were randomly divide into two groups of 34 ones each, both group took orally risperidone and research group was plus venlafaxine for 8 weeks. Before and after treatment, clinieale efficacies were assessed with the Postive and Negative Syndrome Scale （PANSS） and Hamilton Anxiety Scale （HAMA） and adverse reactions with the Treatment Emergent Symptom Scale（TESS）. Results After treatment, the PANSS and HAMA scores lowered more significantly compared with pretreatment in the research （P〈0. 01）, so did only PANSS in the control group （P〈0.01） ; total and negative factors〈 scores of the PANSS and the scores of the HAMA in research were significantly lower than those in control group （P〈0.01） ; at the end of the 8th week, effective rates were respectively 88.24〈 in the research and 64.71% in the control, the former was signifcantly higher than the latter （x2=5. 231,P〈0. 05）. Adverse reactions of both groups were mild, there were no significant differences in incidences of adverse rcactions between 2 groups （P〈0.05）. Conclusion Risperidone plus venlafaxine can effectively improve negative and anxiety symptoms of schizo phrenia and increase clinical efficacy notably, and has higher safety and better compliance.